"RIV/00669806:_____/13:10159071!RIV14-MZ0-00669806" . . "CZ - \u010Cesk\u00E1 republika" . . . . "Entecavir v l\u00E9\u010Db\u011B chronick\u00E9 virov\u00E9 hepatitidy B" . "Hepatitis B (HBV) virus infection is one of the most important infections worldwide and is mainly associated with the risk of chronic hepatitis B that progresses into the stage of advance fibrosis or cirrhosis, often decompensating with the resulting development of hepatocellular carcinoma. Most advanced countries currently experience declining incidence rates of new cases (infections) with HBV as a result of vaccination. Drugs used to treat the condition differ in their indications (mainly IFN vs. antiviral drugs), their efficacy and resistance development. Treatment with entecavir is efficacious, effective, very safe and results in significantly reduced viraemia (or the virus becoming negative) within the first 52 weeks of treatment that should be continued for at least another 5 years. Resistance development is rare, and patients resistant to lamivudine may be effectively treated with higher entecavir doses."@en . "Entecavir v l\u00E9\u010Db\u011B chronick\u00E9 virov\u00E9 hepatitidy B" . "RIV/00669806:_____/13:10159071" . . . "N\u00E1kaza virem hepatitidy B (HBV) je celosv\u011Btov\u011B jednou z nejv\u00FDznamn\u011Bj\u0161\u00EDch infekc\u00ED, jej\u00EDmi\u017E nejv\u011Bt\u0161\u00EDmi riziky je progrese onemocn\u011Bn\u00ED do stadia pokro\u010Dil\u00E9 fibr\u00F3zy \u010Di cirh\u00F3zy s rizikem jej\u00ED dekompenzace a rozvoj hepatocelul\u00E1rn\u00EDho karcinomu. Ve v\u011Bt\u0161in\u011B vysp\u011Bl\u00FDch zem\u00ED doch\u00E1z\u00ED v sou\u010Dasnosti k poklesu incidence nov\u00FDch p\u0159\u00EDpad\u016F (n\u00E1kaz) HBV v d\u016Fsledku vakcinace. Pou\u017E\u00EDvan\u00E9 l\u00E9ky se li\u0161\u00ED v indikac\u00EDch (p\u0159edev\u0161\u00EDm IFN vs. antivirotika), v \u00FA\u010Dinnosti a riziku rozvoje rezistence. L\u00E9\u010Dba entecavirem je \u00FA\u010Dinn\u00E1, efektivn\u00ED, velmi bezpe\u010Dn\u00E1 a vede k signifikantn\u00EDmu poklesu vir\u00E9mie (resp. jej\u00ED negativizaci) b\u011Bhem prvn\u00EDch 52 t\u00FDdn\u016F l\u00E9\u010Dby, kter\u00FD trv\u00E1 minim\u00E1ln\u011B n\u00E1sleduj\u00EDc\u00EDch 5 let l\u00E9\u010Dby. Vznik rezistenze je vz\u00E1cn\u00FD, u pacient\u016F s ji\u017E vytvo\u0159enou rezistenc\u00ED na lamivudin mohou b\u00FDt vy\u0161\u0161\u00ED d\u00E1vky entecaviru \u00FA\u010Dinn\u00E9." . "Farmakoterapie" . . "Entecavir v l\u00E9\u010Db\u011B chronick\u00E9 virov\u00E9 hepatitidy B"@cs . . "5"^^ . "N\u00E1kaza virem hepatitidy B (HBV) je celosv\u011Btov\u011B jednou z nejv\u00FDznamn\u011Bj\u0161\u00EDch infekc\u00ED, jej\u00EDmi\u017E nejv\u011Bt\u0161\u00EDmi riziky je progrese onemocn\u011Bn\u00ED do stadia pokro\u010Dil\u00E9 fibr\u00F3zy \u010Di cirh\u00F3zy s rizikem jej\u00ED dekompenzace a rozvoj hepatocelul\u00E1rn\u00EDho karcinomu. Ve v\u011Bt\u0161in\u011B vysp\u011Bl\u00FDch zem\u00ED doch\u00E1z\u00ED v sou\u010Dasnosti k poklesu incidence nov\u00FDch p\u0159\u00EDpad\u016F (n\u00E1kaz) HBV v d\u016Fsledku vakcinace. Pou\u017E\u00EDvan\u00E9 l\u00E9ky se li\u0161\u00ED v indikac\u00EDch (p\u0159edev\u0161\u00EDm IFN vs. antivirotika), v \u00FA\u010Dinnosti a riziku rozvoje rezistence. L\u00E9\u010Dba entecavirem je \u00FA\u010Dinn\u00E1, efektivn\u00ED, velmi bezpe\u010Dn\u00E1 a vede k signifikantn\u00EDmu poklesu vir\u00E9mie (resp. jej\u00ED negativizaci) b\u011Bhem prvn\u00EDch 52 t\u00FDdn\u016F l\u00E9\u010Dby, kter\u00FD trv\u00E1 minim\u00E1ln\u011B n\u00E1sleduj\u00EDc\u00EDch 5 let l\u00E9\u010Dby. Vznik rezistenze je vz\u00E1cn\u00FD, u pacient\u016F s ji\u017E vytvo\u0159enou rezistenc\u00ED na lamivudin mohou b\u00FDt vy\u0161\u0161\u00ED d\u00E1vky entecaviru \u00FA\u010Dinn\u00E9."@cs . "72984" . "Hejda, V\u00E1clav" . "9" . "Entecavir for the treatment of chronic hepatitis B infection"@en . "entecavir; viraemia; antiviral drugs; hepatitis B"@en . . . . . . "1801-1209" . "[3880C5679A26]" . "4" . . "1"^^ . "Entecavir for the treatment of chronic hepatitis B infection"@en . "Entecavir v l\u00E9\u010Db\u011B chronick\u00E9 virov\u00E9 hepatitidy B"@cs . . "I" . "1"^^ . .